The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance-Reference-Cited by-同舟云学术

The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance

Published:2015-06-22 Issue:3 Volume:55 Page:318-328
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Butzke Bettina¹,Oduncu Fuat S.²,Severin Franziska¹,Pfeufer Arne³,Heinemann Volker⁴,Giessen-Jung Clemens⁴,Stollenwerk Björn¹,Rogowski Wolf H.¹⁵

Affiliation:

1. Institute for Health Economics and Healthcare Management, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

2. Division Hematology and Oncology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany

3. Institute for Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

4. Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Munich, Germany

5. Ludwig-Maximilians-Universität München, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Munich, Germany

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/0284186X.2015.1053983

Reference53 articles.

1. Challenges of translating genetic tests into clinical and public health practice

2. Personalized medicine in oncology: where have we come from and where are we going?

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

2. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study;Pharmacological Research;2023-11

3. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis;Value in Health Regional Issues;2023-09

4. UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety;Pharmacogenomics;2023-06

5. Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients;European Journal of Cancer;2022-09